Latest Capital Raises News

Dataworks Group Limited reported a modest revenue increase and a reduced net loss for FY25, underpinned by major contract wins in Canada and Australia. The company is targeting cashflow positivity in the first half of FY26 following operational efficiencies and capital raises.

Cyprium Metals Limited has launched an A$80 million capital raise to fast-track the restart of its Nifty Copper Complex, aiming to unlock significant value from its brownfield assets. The funds will support refurbishment, feasibility studies, and strengthen the company’s balance sheet.

Papyrus Australia has marked significant progress in July 2025 with successful testing at its Rapid Prototyping facility and advancing plans for a commercial production site, while also writing down key investments.

AssetOwl Limited reports a modest net profit for FY2025, driven by a significant gain on debt extinguishment, while grappling with ASX suspension and ongoing going concern challenges.

Althea Group Holdings reports a significant reduction in losses for FY25, driven by asset sales and strategic refocus on North American THC beverages. The company completed a $4 million capital raise and navigated leadership changes amid subsidiary liquidations.

OMG Group Limited reported a 63% revenue surge to $4.13 million in FY2025, driven by its acquisition of Good Oats Pty Ltd and strong growth in its Blue Dinosaur brand. The company also trimmed its loss by 18% and improved gross margins, signaling operational progress despite ongoing challenges.

Cardiex Limited’s FY2025 results reveal a sharp 67% revenue decline driven by the prior year’s one-off clinical trial payment, while net losses nearly doubled despite ongoing cost reduction efforts and significant capital raises.

Equity Story Group reported a 9.1% revenue increase driven by its Securities division and reduced its net loss by 14.5% for FY2025. However, the company’s net liabilities grew and cash reserves sharply declined, raising questions about its financial footing.

Cambium Bio reported a $3.84 million loss for FY25 but secured critical FDA approvals and ethics clearances to initiate Phase 3 trials of Elate Ocular®, supported by a $2.12 million capital raise.

1414 Degrees Ltd reported a widened net loss of $3.34 million for FY25 while advancing its thermal energy storage and hydrogen reactor technologies, supported by fresh equity and government grants.

Assetora Limited reported a reduced loss of $3.35 million for FY2025 despite an 18% revenue decline, focusing on capital raising and fund growth to stabilize operations.

ZMM has reported a significant turnaround with a $815,877 net profit for FY2025, reversing last year’s $3.25 million loss, though net tangible assets per security have halved and auditors flag going concern uncertainty.